Oncoinvent
The company develops Radspherin, a radiopharmaceutical product candidate designed to treat metastatic cancers in the peritoneal cavity, such as ovarian and colorectal cancer. The technology utilizes inorganic microparticles as carriers for alpha-emitters to deliver high-power radiation with a short range directly to tumor cells. Their clinical pipeline currently includes Phase 2 studies focused on regional retention of effective radiation doses while minimizing systemic exposure.
Biotechnology
Radiopharmaceuticals
Oncology
Healthtech
Funding summary
- Total raised
- €3.7M
- Funding rounds
- 1
Investors in Oncoinvent
Investors on record for Oncoinvent. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Oncoinvent?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors